DEVELOPING INNOVATIVE CELLULAR THERAPIES FOR CNS DISEASE
A UNIQUE APPROACH
Q Therapeutics has adopted a unique approach to developing human cell-based therapies for debilitating – and currently incurable – diseases of the brain and spinal cord (the central nervous system, or CNS). Our revolutionary approach focuses on glial cells – non-neuronal cells in the CNS that are essential for supporting, repairing and maintaining normal neuron function and health.
Q-Cells® – our first cellular therapeutic candidate – are human glial progenitor cells that give rise to two types of specialized glial cells, astrocytes and oligodendrocytes. In pre-clinical studies, Q-Cells® have been shown to successfully replicate, migrate and differentiate at sites of CNS injury and disease, with resulting improvements in both function and survival, and no observed toxicity.
Q Thera now has FDA allowance for an IND application to proceed with a Phase 1/2a clinical trial of Q-Cells® in patients with Transverse Myelitis, a crippling inflammation of the spinal cord that affects approximately 40,000 people in the US. Similar to Multiple Sclerosis, TM destroys the myelin sheath surrounding nerve fibers in the spinal cord, compromising muscle control and affecting sensation.
After a decade of research, development and validation, we are now leading a novel stem cell therapeutic approach to CNS disease through replacing myelin and restoring neuronal function with a human glial progenitor cell technology platform.
Positioned to revolutionize the treatment of neurodegenerative diseases, our first cellular therapeutic product – Q-Cells® – provides a healthy population of glia to sites of CNS injury or disease, where these highly potent, highly purified cells perform the neuron repair functions for which they have evolved.
Not harvested from the patient – Q-Cells® are an allogeneic cell therapy delivered to the site as an off-the-shelf pharmaceutical product that is ready to be injected for therapeutic use.
No genetic manipulation – Q-Cells® are isolated and purified from brain tissue, so they are natural CNS cells in their natural state performing their natural function.
Small-volume injection – Each vial of Q-Cells® contains millions of human glial progenitor cells, with the capacity to multiply and differentiate into millions of astrocytes and oligodendrocytes.
Long-lived in the CNS – Q-Cells® survive in the CNS longer than mesenchymal stem cells (MSCs), with the potential to provide long-lasting effects.
Q Therapeutics, Inc.
417 Wakara Way, Suite 3510
Salt Lake City